buoyed by approval to resume artificial heart trial
Send a link to a friend
[May 03, 2017] (Reuters)
- Artificial heart maker Carmat has
obtained approval from France's national drugs agency (ANSM) to resume a
heart implant trial, sending the company's shares more than one fifth
higher on Wednesday.
"Carmat has provided the elements allowing for the resumption of the
trial, meeting satisfactory conditions of safety and risk control,"
ANSM said in a statement late on Tuesday.
ANSM had ordered Carmat to suspend further implants last December
following the death of a patient in October.
The patient who died had the artificial heart implanted at the end
of August last year and is the fifth patient to die with one fitted.
He was the first of 20 patients in a second so-called 'pivotal'
phase of tests, which is a prerequisite to market the product in the
Carmat's products could represent a major medical breakthrough if
proven reliable. They are designed for people with end-stage heart
failure, a deadly condition where the heart is unable to pump blood
adequately around the body.
In a statement, Carmat also said it continued to take steps to
expand this trial into other countries, and was preparing to open a
new production site to strengthen the industrial means necessary to
carry out the study.
[to top of second column]
"The site should be operational by the end of the year and would
also eventually enable the manufacturing requirements for the
prosthesis' first commercial launch phases to be met," it said.
Carmat's shares, which fell to multi-year lows following the earlier
halting of the heart implants tests, rose 21 percent to by 0720 GMT.
(Reporting by Wout Vergauwen and Pawel Lapinski. Editing by Jane
[© 2017 Thomson Reuters. All rights
Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.